On September 22, 2021 Onco360, the nation’s largest independent Oncology Pharmacy, reported that it has been selected by Takeda to be a specialty pharmacy partner for EXKIVITY (mobocertinib), the first oral treatment option for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy (Press release, Onco360, SEP 22, 2021, View Source [SID1234590144]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Onco360 is excited to become a specialty pharmacy provider for EXKIVITY patients," said Benito Fernandez, Chief Commercial Officer, Onco360. "As a provider of this important treatment option for patients, Onco360 is committed to supporting the highly specialized needs of locally advanced or metastatic NSCLC patients with EGFR exon 20 insertion mutations and their physicians across the United States."

According to the National Cancer Institute‘s (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, approximately 235,760 patients will be diagnosed with lung cancer in 2021 with a corresponding 131,880 deaths. Approximately 85% of lung cancer cases are represented by NSCLC. When considering all subtypes of lung cancer as well as stages of the disease, lung cancer patients have a poor five-year overall survival (OS) of 21.7%. Unfortunately, 56% of lung cancer patients will have incurable, metastatic disease at the time of initial diagnosis.1 Approximately 0.1 to 4% of all NSCLC patients have EGFR exon 20 insertion mutations.2

EXKIVITY is manufactured by Takeda, a commercial-stage biotechnology company. The FDA’s approval of EXKIVITY is based upon the results of a pooled subset of patients with EGFR exon 20 insertion mutation-positive locally advanced or metastatic NSCLC whose disease had progressed on or after platinum-based chemotherapy who were enrolled in the international, open-label, multicohort Phase I/II AP32788-15-101 (NCT02716116) clinical trial. This data demonstrated that EXKIVITY administration resulted in a 28% overall response rate (ORR) in this patient population.3 For full prescribing information, visit EXKIVITY.com.